Key Points
- Halozyme CEO Helen Torley sold 20,000 shares on May 12 at an average price of $71.75, totaling about $1.44 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, Torley still owned 767,780 shares valued at roughly $55.1 million, and the sale reduced her position by 2.54%. She also disclosed additional recent sales, bringing her recent total to 30,000 shares sold.
- Halozyme reported strong quarterly results, with EPS of $1.60 beating estimates and revenue rising 42.2% year over year to $376.7 million. Analysts currently rate the stock a Moderate Buy with an average target price of $80.67.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,122,698.20. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Torley also recently made the following trade(s):
- On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.
- On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total transaction of $635,000.00.
- On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00.
- On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $70.21, for a total transaction of $702,100.00.
- On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $1,393,800.00.
Halozyme Therapeutics Stock Down 1.3%
Shares of HALO stock opened at $70.03 on Thursday. The company has a market capitalization of $8.30 billion, a price-to-earnings ratio of 25.19, a PEG ratio of 0.29 and a beta of 0.89. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22. The company's fifty day moving average price is $65.71 and its 200-day moving average price is $68.63. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 3.66.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company's revenue was up 42.2% on a year-over-year basis. During the same period last year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current fiscal year.
Institutional Trading of Halozyme Therapeutics
Hedge funds have recently bought and sold shares of the stock. Clark Capital Management Group Inc. boosted its stake in Halozyme Therapeutics by 14.4% during the third quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company's stock worth $14,885,000 after buying an additional 25,582 shares during the period. Intech Investment Management LLC raised its stake in shares of Halozyme Therapeutics by 46.0% in the third quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company's stock valued at $10,903,000 after acquiring an additional 46,850 shares during the period. Allworth Financial LP raised its stake in shares of Halozyme Therapeutics by 322.5% in the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company's stock valued at $2,914,000 after acquiring an additional 30,331 shares during the period. ING Groep NV purchased a new stake in shares of Halozyme Therapeutics in the third quarter valued at $6,652,000. Finally, Element Squared LLC purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at $1,193,000. Hedge funds and other institutional investors own 97.79% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the stock. Benchmark raised their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a research report on Tuesday. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 19th. Wall Street Zen cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Saturday, February 21st. Finally, TD Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $80.67.
Read Our Latest Stock Analysis on Halozyme Therapeutics
Trending Headlines about Halozyme Therapeutics
Here are the key news stories impacting Halozyme Therapeutics this week:
- Positive Sentiment: Halozyme beat Q1 estimates, with revenue rising about 42% year over year to $376.7 million and EPS coming in above expectations, helping support investor confidence in the company’s growth outlook. Article Title
- Positive Sentiment: The company also highlighted a new $1 billion share repurchase authorization and reiterated full-year guidance, which can be viewed as a signal of management confidence and a potential support for the share price. Article Title
- Positive Sentiment: Halozyme announced a global collaboration and license agreement with GSK for its ENHANZE drug-delivery technology, potentially expanding its long-term royalty stream if partnered programs progress. Article Title
- Neutral Sentiment: Morgan Stanley trimmed its price target on Halozyme to $93 from $96, but kept an overweight rating, so the note was not a major negative for the stock. Article Title
- Negative Sentiment: CEO Helen Torley disclosed two recent stock sales totaling 30,000 shares under a pre-arranged 10b5-1 plan, which may weigh on sentiment even though the trades were planned in advance. Article Title
Halozyme Therapeutics Company Profile
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
